This review focuses on patient care tips and practices for the care of patients with B-NHL or MM receiving bispecific antibody therapy.

Researchers have developed a novel antibody-based enzyme switch that converts antibody–antigen binding into enzyme activity, paving the way from detection via bioluminescence to the control of ...

VITT antibodies feature an oligoclonal or monoclonal antibody profile with a remarkable degree of clonal identity of the light chains, 3,4 which results in a strikingly similar structure of the ...

Around the same time that Rosenberg assembled an army of the most successful T cells he could find, others developed strategies to arm these immune soldiers. The field of cell engineering took off in ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid tumors. On June 1, 2025, The Lancet published positive results from the ...

Study introduces TRACeR-I, a protein platform with broad HLA compatibility, paving the way for advanced immune response engineering and disease-specific targeting. Study: Targeting peptide antigens ...

Snakebite envenoming is a neglected tropical disease, with an estimated 1.8 to 2.7 million cases occurring each year. Snake venoms, complex protein cocktails with diverse toxicity profiles, can cause ...

Researchers at the University of Chicago have developed a modular cancer immunotherapy that can be switched on, off or reprogramed to attack different cancers. Promising initial testing results, ...

Solve Therapeutics Inc. has disclosed new antibody-drug conjugates (ADCs) comprising antibody or antigen binding fragments targeting trophoblast glycoprotein (TPBG; 5T4) linked to a cytotoxic drug and ...